Menu
Not yet recruiting NCT07562009

Investigation of Allergen Sensitization in Newborn Babies Diagnosed With Necrotizing Enterocolitis.

No phase Interventional Necrotizing Enterocolitis Allergy Preterm

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: skin prick test.
Who it may be relevant to
Registry conditions: Necrotizing Enterocolitis, Allergy, Preterm. Basic parameters: 12 months — 24 months · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Allergy Risk and Sensitization Following Necrotizing Enterocolitis

Overview

To evaluate the frequency of allergy between 12 and 24 months of age in infants who were treated in the neonatal clinic and had NEC. To investigate the relationship between NEC development and the development of allergy in the later period.

Interventions

  • Diagnostic test skin prick test
    Skin Prick Test Procedure: The SPT was performed when patients were free of acute health problems, and medications that could affect test results had been discontinued. A histamine solution (10 mg/mL, ALK-Abelló®, Canada) was used as a positive control, and 0.9% sodium chloride was used as a negative control. The test was performed on the volar surface of the forearm, and results were read after 20 minutes. A wheal ≥3 mm greater than the negative control, with erythema, was considered positive

Primary outcome measures

  • The effect of necrotizing enterocolitis development in premature infants on response to allergens. [Time frame: Through study completion, an average of 1 year]

Eligibility criteria

Inclusion criteria

  • Infants born in our hospital and diagnosed with NEC during the study period.
  • Age-matched control infants born in our hospital during the same period but without NEC diagnosis.
  • Written and verbal informed consent obtained from at least one parent.

\-

Exclusion criteria

  • Infants whose parents did not provide written or verbal consent.
  • Infants with major congenital anomalies.
  • Infants with chromosomal disorders.
  • Infants with gastrointestinal malformations (e.g., duodenal atresia, gastroschisis, omphalocele).
  • Infants diagnosed with immunodeficiency. -

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Non-randomized
Model
Crossover
Masking
Open label
Primary purpose
Diagnostic

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07562009 · 2026-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗